[2-chloro-6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methanol | 1228303-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [2-chloro-6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methanol
• CAS: 1228303-91-0
• 化学式: C₁₂H₈Cl₂N₂OS
• 分子量: 299.18
• InChiKey: AIRWWXVKDIGELV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 2-chloro-6-p-chlorophenylimidazo[2,1-b]thiazole 在 sodium acetate 、 溶剂黄146 、 sodium hydroxide 作用下， 以 水 、 甲醇 为溶剂， 反应 5.0h， 生成 [2-chloro-6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methanol
  参考文献：
  名称：

  [EN] IMIDAZOPYRIDINE COMPOUNDS
  [FR] COMPOSÉS IMIDAZOPYRIDINES

  摘要：

  这项发明涉及式(I)的化合物及其药学上可接受的盐和溶剂化合物，这些化合物是SSAO活性的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗或预防抑制SSAO活性有益的医疗状况，如炎症性疾病和免疫紊乱。

  公开号：

  WO2010064020A1

文献信息

• Imidazopyridine Compounds
  申请人：Nilsson Marianne

  公开号：US20120010188A1

  公开（公告）日：2012-01-12

  The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  本发明涉及公式（I）的化合物及其药学上可接受的盐和溶剂化物，它们是SSAO活性抑制剂。本发明还涉及包含这些化合物的药物组合物和使用这些化合物治疗或预防抑制SSAO活性有益的医疗条件，例如炎症性疾病和免疫紊乱。
• IMIDAZOPYRIDINE COMPOUNDS
  申请人：Proximagen Limited

  公开号：US20150239905A1

  公开（公告）日：2015-08-27

  The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  本发明涉及式(I)的化合物及其药学上可接受的盐和溶剂，它们是SSAO活性的抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物治疗或预防抑制SSAO活性有益的医疗状况，例如炎症性疾病和免疫障碍。
• NEW THERAPEUTIC USES OF ENZYME INHIBITORS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160113893A1

  公开（公告）日：2016-04-28

  The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.
• Therapeutic uses of enzyme inhibitors
  申请人：Proximagen Limited

  公开号：US20160101072A1

  公开（公告）日：2016-04-14

  The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1/SSAO activity, and their use for the treatment of muscular dystrophy.
• VAP-1 INHIBITORS FOR TREATING PAIN
  申请人：BENEVOLENTAI CAMBRIDGE LIMITED

  公开号：US20200397764A1

  公开（公告）日：2020-12-24

  This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.